Telix Pharmaceuticals Lists ADRs on Nasdaq Following Merger

Telix Pharmaceuticals Limited announced it is utilizing the Nasdaq exchange for its American Depositary Receipt (ADR) listing. This follows a transaction where an upfront consideration of US$1.65 billion was provided to ITM Shareholders, resulting in an expected payout of approximately US$1.25 billion in Telix Shares at US$11.84 per share. The merger aims to create a vertically integrated radiopharmaceutical company.

The transaction integrates ITM’s core radioisotope production capabilities, which significantly contribute to cash generation for Telix Pharmaceuticals Limited. ITM is noted as a leading supplier of therapeutic radioisotopes, and its complementary pipeline includes a Phase 3 candidate, ITM-11, potentially accelerating Telix’s market entry into targeted radionuclide therapy.